This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|April 21, 2005
Drug Recalls
Author(s)Pharmaceutical Technology Editors
Drug Recall
Advertisement
The US Food and Drug Administration has logged three
- On March 15, McKesson Packaging Services (Concord, NC), startedsending out letters recalling 4755 boxes of institutional-useSky brand blister packs and punch cards of acetaminophen (manufacturedby Magno-Humphries Laboratories of Tigard, OR) that might contain metalparticles.
- On March 11, Malinckrodt (Berkeley, MO) began its recall of1194 thousand-tablet bottles of propoxyphene napsylate andacetaminophen tablets because the bottle label referred to pinktablets, while those batches of the product were white.
- On April 4, Wyeth's Richmond Division (Richmond, VA) becanrecalling 28,727 thousand-tablet bottles of Premarin conjugatedestrogen tablets (in 0.625 and 0.3 mg dosages), citing dissolution failures.
–Douglas McCormick
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement